Clinicopathological and prognostic significance of Ras Association and Pleckstrin Homology domains 1 (RAPH1) in breast cancer by Kurozumi, Sasagu et al.
Clinicopathological and prognostic significance of Ras Association and Pleckstrin 
Homology domains 1 (RAPH1) in breast cancer 
Sasagu Kurozumi1,2, Chitra Joseph1, Sultan Sonbul1, Mohammed A Aleskandarany1,3, Marian 
Pigera1, Mansour Alsaleem1, Sami Alsaeed1, Yousif Kariri1, Christopher C Nolan1, Maria 
Diez-Rodriguez1, Simon Johnston1, Nigel P. Mongan4,5, Takaaki Fujii2, Ken Shirabe2, Stewart 
G Martin1, Ian O Ellis1, Andrew R Green1 and Emad A Rakha1,3 
1Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of 
Medicine, University of Nottingham, Nottingham, UK; 2Department of General Surgical 
Science, Gunma University Graduate School of Medicine, Gunma, Japan; 3Faculty of 
Medicine, Menoufyia University, Shebin al Kawm, Egypt; 4Cancer Biology and Translational 
Research, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, 
UK; 5Department of Pharmacology, Weill Cornell Medicine, New York, 10065, USA. 
Corresponding author:  
Professor Emad Rakha 
Department of Histopathology, Division of Cancer and Stem Cells, School of Medicine, The 
University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City 
Hospital, Nottingham, NG5 1PB, UK 
Email: Emad.Rakha@nottingham.ac.uk 
RUNNING TITLE: Prognostic value of RAPH1 in breast cancer 
!1
ABSTRACT 
BACKGROUND:  Ras association and pleckstrin homology domains 1 (RAPH1) is 
involved in cytoskeleton regulation and re-epithelialisation in invasive carcinoma and 
therefore may play a key role in carcinogenesis and metastasis. We herein investigated the 
biological and clinical significance of RAPH1 in breast cancer using large annotated cohorts. 
METHODS: The clinicopathological and prognostic significance of RAPH1 was assessed at 
the genomic and transcriptomic levels using The Cancer Genome Atlas (TCGA) dataset 
(n=1039) and the results were validated using the Molecular Taxonomy of Breast Cancer 
International Consortium (METABRIC) cohort (n=1980). RAPH1 protein expression was 
evaluated by immunohistochemistry in a large, well-characterised cohort of early-stage breast 
cancer (n=1040). 
RESULTS: In both the TCGA-BRCA and METABRIC cohorts, RAPH1 mRNA expression 
and RAPH1 copy number alteration were strongly correlated. RAPH1 mRNA overexpression 
was significantly correlated with high expression of adhesion and EMT markers including 
CDH1, TGFβ1 and CD44. RAPH1 mRNA overexpression was a significant predictor of a 
poor prognosis (Hazard ratio: 3.88; p = 0.049). High RAPH1 protein expression was 
associated with higher grade tumours with high proliferation index, triple negative phenotype 
and high E-cadherin expression. High RAPH1 protein expression was an independent 
predictor of shorter survival (Hazard ratio: 4.37; p = 0.037). 
CONCLUSIONS: High RAPH1 expression is correlated with aggressive breast cancer 
phenotypes and provides independent prognostic value in invasive breast cancer. 
Keywords: invasive breast cancer; lymphovascular invasion; ras association and pleckstrin 
homology domains 1; re-epithelialisation; E-cadherin 
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INTRODUCTION 
Recent developments in diagnostic accuracy and drug therapies have improved 
outcomes in early-stage breast cancer (BC). However, more than 20% of BC patients have 
poor clinical outcomes related to recurrence and metastasis [1, 2]. Various studies have been 
conducted to identify factors associated with tumour invasion and metastasis to uncover 
novel candidates for targeted treatment. 
Ras association and pleckstrin homology domains 1 (RAPH1), also referred to as 
lamellipodin (LPD) [3], acts as a downstream effector of the Ras pathway [4], which plays an 
important role in epithelial-mesenchymal transition (EMT) [5, 6]. EMT is thought to play an 
important role in the development of distant metastasis in BC [7]. Previous studies showed 
changes in intracellular tight junction characteristics and weakened cell adhesive properties 
during EMT as underlying mechanisms inducing the loss of epithelial features and the gain of 
mesenchymal morphology [8, 9].  RAPH1 has a role in regulating cell migration and re-
epithelialisation [10]. Aberrant expression of RAPH1 may also promote cancer cell adhesion 
at distant, metastatic sites [10]. However, the clinical significance and prognostic role of 
RAPH1 in BC remains to be defined.  
In this study, RAPH1 was investigated in BC at the gene and protein phases using 
large well-characterised and annotated cohorts of early stage BC with emphasis on the 
relation between RAPH1 expression and clinicopathological factors including the biomarkers 
associated with EMT and patients’ outcomes.  
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MATERIALS AND METHODS   
Genomic and transcriptomic analysis of RAPH1 gene  
In this study, the Cancer Genome Atlas (TCGA) [11] dataset (n = 1039) provided by 
cBioPortal [12] was used for copy number and mRNA analysis of RAPH1 gene. Briefly, 
RAPH1 copy number alteration (CNA) datasets from Affymetrix SNP 6.0 arrays and RAPH1 
mRNA expression data from RNASeqV2 were accessed, and information on several 
clinicopathological factors and outcomes were also collected. 
The Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) 
dataset [13, 14] including 1980 patients was used for validation of the findings based on the 
TCGA dataset. In this cohort, patients with oestrogen receptor (ER)-positive tumours with 
negative lymph node metastasis did not receive adjuvant chemotherapy, whereas those with 
ER-negative or lymph node metastasis-positive tumours received adjuvant chemotherapy. No 
patients with HER2-positive BC were treated with trastuzumab. 
RAPH1 protein analysis expression 
A total of 1040 BC patients who underwent surgery at Nottingham City Hospital in 
the UK between 1987 and 1998 were included in this study. Characteristics of the 1040 cases 
are shown in Supplementary Table 1. All patients underwent breast-conserving surgery or 
modified radical mastectomy without receiving neoadjuvant treatment. A total of 405 (38.9%) 
cases had endocrine therapy and 212 (20.4%) patients were treated with chemotherapy. 
Haematoxylin & eosin staining and immunostaining with antibodies against CD34 and D2-40 
according to our previously published methods [15] were used for assessment of 
lymphovascular invasion (LVI) status. Availability and assessment of oestrogen receptor 
(ER), progesterone receptor (PR), HER2, the proliferation marker Ki67, EMT related genes 
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(E-cadherin and N-cadherin), basal markers (CK5/6 and EGFR), and the stem cell markers 
(CD24 and CD44) were described in previous studies [16-22]. This study was approved by 
the Nottingham Research Ethics Committee 2 (Reference title: Development of a molecular 
genetic classification of breast cancer). This study was conducted in accordance with the 
Declaration of Helsinki, and all patients participated in the study after informed consent.  
Specificity of the RAPH1 antibody (HPA016744, Merck, Germany) was confirmed 
by Western blotting using Jurkat and MCF7 cell lines (The American Type Culture 
Collection; Rockville, MD, USA), which indicated a specific band at approximately 130 kDa 
(Supplementary Figure 2). RAPH1 protein expression was assessed in 15 full-face slides of 
BC with aggressive phenotype for evaluation of its association with morphological 
characteristics. Tumour samples, available as 0.6-mm cores, were arrayed as previously 
described [23]. For IHC, the Novolink Max polymer detection system (RE7280-k, Leica, 
Newcastle, UK) was used to visualise the reaction. . Following optimisations, the primary 
antibody for anti-RAPH1 was diluted 1:300 in Bond primary antibody diluent (Leica, 
Germany). For the staining control, a polyclonal rabbit anti-human beta-2 microglobulin 
antibody (1:2000; Dako, Glostrup, Denmark) was used. 3-3' diaminobenzidine 
tetrahydrochloride (Novolink DAB substrate buffer plus) was treated as the chromogen. 
Counter-staining was performed using Meyer’s haematoxylin for 6 minutes. Immunostained 
tissue microarray sections were digitally scanned using a Nano Zoomer (Hamamatsu 
Photonics, Tokyo, Japan). RAPH1 IHC expression was classified into the following groups 
according to the cytoplasmic staining intensity of the cancer cells: no staining, weak staining, 
moderate staining and strong staining (Figure 1). The H-score system, as previously reported 
[24, 25], was used based on intensity scoring (0, negative; 1, weak; 2, moderate and 3, 
strong) and proportion scoring (0–100) based on the cytoplasmic RAPH1 expression pattern. 
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Statistical analysis 
Statistical analyses were conducted using the SPSS statistical software v24.0 (IBM, 
Armonk, NY, USA). The relationship of RAPH1 CNA with RAPH1 mRNA expression was 
examined using analysis of variance test with Bonferroni correction. Pearson correlation test 
was used to evaluate the relationship of RAPH1 mRNA expression with the mRNA 
expression of other genes. The chi-squared test was used to assess differences in protein 
expression level stratified by several clinicopathological factors including tumour size, lymph 
node status and ER and HER2 expression. To assess the association of RAPH1 with 
prognosis, Kaplan–Meier survival curves for BC-specific survival (BCSS) were determined, 
and the log-rank test was conducted. The BCSS in this study was determined as the time from 
the day of surgery to the day of death due to breast cancer. For univariate and multivariate 
survival assessment of clinicopathological factors including RAPH1 expression, 95% 
confidence intervals (CIs) were assessed using the Cox proportional hazards regression 
model. In these analyses based on mRNA expression, median mRNA value was determined 
as a cut-off point. For RAPH1 protein, significant cut-off point was calculated as H-score 90 
using X-Tile (X-Tile Bioinformatics Software, Yale University, version 3.6.1) based on 
patient outcome, and samples were divided into high and low expression groups.  
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RESULTS 
RAPH1 copy number alteration and mRNA expression 
In the TCGA cohort of 1039 patients, RAPH1 copy number gain and RAPH1 loss 
were observed in 99 (9.5%) and 219 (21.1%) cases, respectively. In 1980 patients of the 
METABIRIC cohort, RAPH1 copy number gain and RAPH1 loss were observed in 27 (1.4%) 
and 33 (1.7%) cases, respectively. In both cohorts, RAPH1 mRNA expression was higher in 
the tumours with copy number gain  than in the neutral cases (p < 0.0001) and was lower in 
the tumours with copy number loss than in the neutral cases (both p < 0.0001).  
High RAPH1 mRNA overexpression was associated with higher CDH1 (TCGA: p < 
0.0001; METABRIC: p = 0.0096), lower TGFβ1 (TCGA: p < 0.0001; METABRIC: p = 
0.0011), lower KRT6C (TCGA: p = 0.0059; METABRIC: p = 0.026) and higher CD44 
(TCGA: p < 0.0001; METABRIC: p < 0.0001) expression s in both the TCGA and 
METABRIC cohorts (Table 1). Patients with high RAPH1 mRNA expression had worse 
prognosis than those with low RAPH1 mRNA expression in TCGA cohort (hazard ratio [HR] 
3.88; p = 0.049; Figure 2a), although this was not observed in the METABRIC validation 
cohort (Supplementary Figure 3). 
Immunohistochemical expression of RAPH1 protein 
Among full-face tissue sections, the RAPH1 expression grades and patterns in 
carcinoma cells were apparently different from those of normal mammary glands, as shown 
in Figure 3. RAPH1 expression in normal glandular epithelium was uniformly weak. The 
RAPH1 immunoreactivity of myoepithelial cells was lower than those of glandular cells. In 
contrast, RAPH1 immunopositivity was observed in the cytoplasm of invasive cancer cells, 
which was stronger compared to normal epithelial cells. In intraductal carcinoma cells, the 
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IHC expression pattern of RAPH1 was similar to that of invasive cancer cells, whereas the 
RAPH1 immunoreactivity was stronger than that of normal epithelial cells. The RAPH1 
expression of myoepithelial cells around ductal components was weak, similar to that 
observed in normal myoepithelial cells. In both the invasive and intraductal cancer cells, the 
nuclei of a few cancer cells showed weak to moderate immunoreactivity concomitantly with 
cytoplasmic immunostaining.  
 RAPH1 protein expression 
There were 393 (37.8%) patients with low RAPH1 expression (H-score < 90) and 647 
(62.2%) patients with high RAPH1 expression group (H-score > 90). In univariate analysis, 
the RAPH1 expression was significantly associated with histological grade (p < 0.0001), ER 
status (p = 0.034), intrinsic subtype (p = 0.0088), Ki67 labelling index (p < 0.0001) and E-
cadherin expression (p = 0.0046; Table 2). No correlation between RAPH1 expression and 
other genes, such as N-cadherin, CK5/6, EGFR, CD44 and CD24 were identified (Table 2). 
The BCSS in BC patients with high RAPH1 expression was significantly different 
from that of those with low RAPH1 expression (HR 4.37, p = 0.037; Figure 2b). Univariate 
analysis using the Cox proportional hazards regression model identified high RAPH1 
expression (HR 1.44, p = 0.038), low E-cadherin expression (HR 0.68, p = 0.0023), positive 
lymphovascular invasion (HR 2.89, p < 0.0001), large tumour size (HR 2.99, p < 0.0001), 
positive nodal status (HR 3.20, p < 0.0001) and HER2-positive (HR 4.69, p < 0.0001) and 
triple negative BC (HR 3.45, p < 0.0001) as poor prognostic factors. RAPH1 protein 
expression was an independent poor prognostic factor in multivariate analysis (HR 1.43, p = 
0.046; Table 3). 
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DISCUSSION 
 Cancer cell migration and cancer cell adhesion at distant metastatic sites have key 
roles in BC metastasis. EMT is involved in initial transformation of the primary invasive 
carcinoma to a metastatic phenotype, whereas cell adhesion has its functional effect during 
the establishment of cancer metastasis at distant sites [4, 26, 27]. In present study, although 
RAPH1 protein expression was not associated with the biomarkers related to EMT, RAPH1 
overexpression was significantly associated with high tumour proliferation and E-cadherin 
positivity. Moreover, high RAPH1 mRNA expression was associated with the high mRNA 
expression levels of CDH1, which encodes E-cadherin. Interestingly, there is evidence that 
RAPH1 interacts with E-cadherin [28]. Analysis of RAPH1 protein expression by IHC also 
revealed that its immunoreactivity in normal epithelium, albeit uniformly weak, was higher 
than that in myoepithelial cells. E-cadherin, a member of a transmembrane glycoprotein 
family, is involved in cell-to-cell adhesion [29, 30]. The extracellular domain of E-cadherin is 
involved in cell-cell interactions, whereas the intracellular domain regulates the assembly of 
the actin cytoskeleton via β-catenin, which has an important role in cell adhesion and signal 
transduction [31-33]. Following invasion, migrating BC cells keep or recover epithelial 
characteristic to adhere metastatic sites [34, 35]. Previous studies reported that RAPH1, also 
referred to as Lamellipodin/LPD, regulates formation of lamellipodia on cells and regulated 
cell migration and adhesion [10, 36, 37] by inducing the activity of Ena/VASP and Scar/
WAVE, which are involved in the construction of actin cytoskeleton at the cellular membrane 
to promote invasion and metastasis of BC [3, 36-39]. High expression and membrane 
localisation of the actin regulator RAPH1 was shown to be associated with poor outcomes in 
BC patients [3]. This result suggested that RAPH1 might be associated with cancer cell 
adhesion at distant metastatic sites after LVI. In the present study, a strong RAPH1 
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expression was observed in the cytoplasm of invasive BC cells; therefore, further 
investigation is necessary to elucidate the role of intracellular localisation of RAPH1 on its 
protein activity.  
Previous studies indicated that RAPH1 gene abnormalities were not associated with 
outcomes in BC [38]. Although the number of cases with RAPH1 CNA was limited in the 
current study, with less than 10% of the cases in the TCGA cohort exhibiting copy number 
gain, RAPH1 mRNA expression was strongly associated with RAPH1 CNA. Additionally, the 
association between RAPH1 mRNA expression and outcome was significant. RAPH1 mRNA 
expression was significantly associated with the biomarkers related to cancer stem cells and 
basal type BC. However, there was no association between RAPH1, cancer stem cells and 
basal type BC at the protein expression level. Recent studies suggest that microRNA-203, 
which is considered to be associated with tumour invasion and transformation [40, 41], 
regulated RAPH1 gene expression at the transcriptional level to contribute to re-
epithelialisation [42]. Additionally, microRNA-203 was proposed to inhibit tumour growth 
and metastasis through podoplanin [43]. Further functional studies of aberrant RAPH1 
regulation by microRNA-203 are a reasonable approach to explore the mechanisms of 
metastasis in invasive BC. 
CONCLUSIONS 
RAPH1 expression is associated with aggressive BC phenotypes and E-cadherin 
positivity. High RAPH1 expression is an independent prognostic factor. RAPH1 association 
with proteins involved in cell adhesion at the plasma membrane might promote BC 
metastasis. 
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FIGURE LEGENDS 
Figure 1. Representative tissue microarray images of breast cancer tissue samples 
immunohistochemically stained for RAPH1. 
In the cytoplasm of cancer cells, RAPH1 shows (a) no staining, (b) weak staining, (c) 
moderate staining and (d) strong staining  (magnification: x200 for all images). 
Figure 2. Survival curves of breast cancer patients stratified by RAPH1 expression.  
(a) In TCGA cohort, breast cancer-specific survival is significantly worse in the RAPH1-high 
group than in the RAPH1-low group (p = 0.049). (b) Significant difference is observed in the 
breast cancer-specific survival between RAPH1-high and RAPH1-low tumours at protein 
phase (p = 0.037). 
Figure 3. Morphological characteristics of RAPH1 immunohistochemistry  
(a) Normal mammary gland cells show absent or weak RAPH1 staining (magnification: 
x200). (b) RAPH1 immunoreactivity is uniformly weak in normal epithelial cells and lower 
in myoepithelial cells than in glandular cells (magnification: x400). (c) RAPH1 
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immunoreactivity is significantly different between intraductal cancer cells and the normal 
mammary gland adjacent to the tumour (white arrow: normal mammary gland; back arrow: 
intraductal cancer cells; magnification: x100)). (d) Invasive cancer cells showing strong 
RAPH1 immunoreactivity mainly recognised in the cytoplasm (magnification: x200).
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Table 1. Association of RAPH1 mRNA expression with mRNA expression of other genes associated with EMT related genes, cancer stem cell related 
genes and basal markers 
̴ TCGA cohort METABRIC cohort
Gene names Correlation value p-value Correlation value p-value
CDH1 0.20 < 0.0001* 0.058 0.0096*
CDH2 0.012 0.69 -0.056 0.012*
TGFB1 -0.17 < 0.0001* -0.073 0.0011*
KRT5 -0.09 0.0035* -0.041 0.071
KRT6A -0.053 0.087 -0.047 0.035*
KRT6B -0.058 0.063 -0.055 0.014*
KRT6C -0.085 0.0059* -0.050 0.026*
EGFR -0.024 0.44 -0.017 0.46
CD24 0.025 0.41 0.063 0.0048*
CD44 0.19 < 0.0001* 0.27 < 0.0001*
ALDH1A3 0.086 0.0057* 0.0081 0.72
Abbreviations: TCGA, The Cancer Genome Atlas; METABRIC, The Molecular Taxonomy of Breast Cancer International Consortium.  
* Significant difference p<0.05.
Table 2. Correlation between RAPH1 protein expression and clinicopathological characteristics 
Factors
Expression of RAPH1
Total p-value
Low High
Tumor size
> 2cm 219 (38.8%) 345 (61.2%) 564
0.45
< 2cm 174 (36.6%) 302 (63.5%) 476
Nodal status
Positive 140 (34.7%) 264 (65.4%) 404
0.097
Negative 253 (39.8%) 383 (60.2%) 636
Histological grade
Grade 3 164 (31.0%) 365 (69.0%) 529
< 0.0001*
Grade 1, 2 229 (44.8%) 282 (55.2%) 511
Lymphovascular 
invasion
Positive 170 (40.0%) 255 (60.0%) 425
0.220
Negative 223 (36.3%) 392 (63.7%) 615
ER
Positive 308 (39.6%) 469 (60.4%) 777
0.034
Negative 85 (32.3%) 178 (67.7%) 263
PgR
Positive 242 (39.4%) 372 (60.6%) 614
0.19
Negative 151 (35.5%) 275 (64.6%) 426
HER2
Positive 53 (41.1%) 76 (58.9%) 129
0.41
Negative 340 (37.3%) 571 (62.7%) 911
Subtypes
HR positive/HER2 negative 284 (39.8%) 429 (60.2%) 713
0.0088*HER2 positive 53 (41.1%) 76 (58.9%) 129
Triple negative 56 (28.3%) 142 (71.7%) 198
Ki67
High (> 10%) 145 (27.9%) 374 (72.1%) 519
< 0.0001*
Low (< 10%) 145 (47.1%) 163 (52.9%) 308
E-cadherin
High 146 (32.7%) 300 (67.3%) 446
0.0046*
Low 236 (41.4%) 334 (58.6%) 570
N-cadherin
High 194 (34.7%) 365 (65.3%) 559
0.45
Low 83 (37.6%) 138 (62.4%) 221
CK 5/6
High 67 (39.2%) 104 (60.8%) 171
0.67
Low 321 (37.5%) 536 (62.5%) 857
EGFR
High 74 (35.2%) 136 (64.8%) 210
0.43
Low 311 (38.2%) 503 (61.8%) 814
CD24
High 194 (37.2%) 327 (62.8%) 521
0.30
Low 46 (42.6%) 62 (57.4%) 108
CD44
High 79 (33.1%) 160 (67.0%) 239
0.23
Low 107 (38.1%) 174 (61.9%) 281
Abbreviations: ER, oestrogen receptor; PR, progesterone receptor; HR, hormonal receptor.  
Some variables do not add up to 1040 for all patients due to missing data.                                                                                                                                                                                                                                                                                                                                    
* Significant difference p<0.05.
Table 3. Survival analysis based on clinicopathological characteristics, including RAPH1 protein expression in lymphovascular invasion positive cases 
Factors
Univariate analysis Multivariate analysis 
Hazard Ratio 95% CI p-value Hazard Ratio 95% CI p-value
RAPH1 expression  
Low Reference Reference
High 1.44 1.02-2.02 0.038* 1.43 1.01-2.03 0.046*
Tumor size
< 2cm Reference Reference
> 2cm 2.99 2.07-4.33 < 0.0001* 1.78 1.21-2.62 0.0033*
Nodal status
Negative Reference Reference
Positive 3.20 2.30-4.45 <0.0001* 2.49 1.76-3.53 < 0.0001*
Lymphovascular 
invasion
Negative Reference Reference
Positive 2.89 2.08-4.01 < 0.0001* 2.16 1.52-3.05 < 0.0001*
Subtypes
HR positive/HER2 negative Reference Reference
HER2 positive 4.69 3.18-6.92 < 0.0001* 3.78 2.55-5.63 < 0.0001*
Triple negative 3.45 2.38-4.99 < 0.0001* 3.12 2.14-4.57 < 0.0001*
E-cadherin
Low Reference Reference
High 0.68 0.49-0.95 0.023* 0.67 0.48-0.94 0.019*
Abbreviations: ER, oestrogen receptor; PR, progesterone receptor; HR, hormonal receptor.  
* Significant difference p<0.05.
Supplementary Table 1. Characteristics of the Nottingham primary cohort patients 
Age range (years) Patients (n)
24–40 114
41–59 595
60 and over 331
Menopausal status
Pre 426
Post 614
Tumour size
<2.0 cm 476
>2.0 cm 564
Nodal status
Negative 636
Positive 404
Lymphovascular invasion
Negative 615
Positive 425
Type of breast surgery
Breast-conserving surgery 450
Mastectomy 590
Axillary surgery
Sampling alone 631
Axillary lymph node dissection 404
No surgery 5
Chemotherapy
Yes 212
No 789
Unknown 39
Endocrine therapy
Yes 405
No 597
Unknown 38
